Department of Molecular Medicine and Medical Biotechnology, University Federico II Naples, Italy
CEINGE Biotecnologie Avanzate, Naples, Italy.
Haematologica. 2017 Aug;102(8):1304-1313. doi: 10.3324/haematol.2016.161166. Epub 2017 May 26.
Hereditary hemolytic anemias are a group of disorders with a variety of causes, including red cell membrane defects, red blood cell enzyme disorders, congenital dyserythropoietic anemias, thalassemia syndromes and hemoglobinopathies. As damaged red blood cells passing through the red pulp of the spleen are removed by splenic macrophages, splenectomy is one possible therapeutic approach to the management of severely affected patients. However, except for hereditary spherocytosis for which the effectiveness of splenectomy has been well documented, the efficacy of splenectomy in other anemias within this group has yet to be determined and there are concerns regarding short- and long-term infectious and thrombotic complications. In light of the priorities identified by the European Hematology Association Roadmap we generated specific recommendations for each disorder, except thalassemia syndromes for which there are other, recent guidelines. Our recommendations are intended to enable clinicians to achieve better informed decisions on disease management by splenectomy, on the type of splenectomy and the possible consequences. As no randomized clinical trials, case control or cohort studies regarding splenectomy in these disorders were found in the literature, recommendations for each disease were based on expert opinion and were subsequently critically revised and modified by the Splenectomy in Rare Anemias Study Group, which includes hematologists caring for both adults and children.
遗传性溶血性贫血是一组由多种原因引起的疾病,包括红细胞膜缺陷、红细胞酶缺乏症、先天性红细胞生成异常性贫血、地中海贫血综合征和血红蛋白病。由于受损的红细胞在通过脾脏红髓时被脾脏巨噬细胞清除,因此脾切除术是治疗严重受累患者的一种可能的治疗方法。然而,除了遗传性球形红细胞增多症,脾切除术的有效性已得到充分证实,在该组中的其他贫血症中脾切除术的疗效尚未确定,并且存在短期和长期感染和血栓并发症的担忧。根据欧洲血液学协会路线图确定的优先事项,我们为每种疾病生成了具体的建议,除了地中海贫血综合征,因为针对该疾病有其他最近的指南。我们的建议旨在使临床医生能够在脾切除术、脾切除术的类型以及可能的后果方面做出更明智的疾病管理决策。由于在文献中未发现关于这些疾病的脾切除术的随机临床试验、病例对照或队列研究,因此针对每种疾病的建议均基于专家意见,并随后由脾切除术治疗罕见贫血研究小组进行了严格审查和修改,该小组包括治疗成人和儿童的血液学家。